{"id":"W2143000374","doi":"10.1007/s00417-012-2123-4","title":"Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines","year":2012,"lang":"en","type":"review","venue":"Graefe s Archive for Clinical and Experimental Ophthalmology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"Dalhousie University","funders":"Novartis Pharma","keywords":"Pegaptanib; Ranibizumab; Medicine; Bevacizumab; Macular degeneration; Intensive care medicine; Aflibercept; Clinical trial; European union; Ophthalmology; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.02331522,0.0004218813,0.004001832,0.0001858171,0.0003910318,0.00004941526,0.0003670924,0.0003330791,0.0000378789],"category_scores_gemma":[0.003254709,0.0002546921,0.0004019153,0.0001489065,0.001878127,0.0001601981,0.0001867127,0.0006582405,0.00000706039],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007991162,"about_ca_system_score_gemma":0.0001205741,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008144167,"about_ca_topic_score_gemma":0.00002042666,"domain_scores_codex":[0.9902186,0.003559445,0.004947912,0.0006886502,0.00008794534,0.000497473],"domain_scores_gemma":[0.974544,0.0204066,0.004449818,0.0004361125,0.00003067799,0.0001328173],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001416323,0.002009935,0.8663245,0.01300058,0.006002622,0.00003258866,0.0268577,0.00002778975,0.000001600573,0.05355273,0.0008707857,0.02990278],"study_design_scores_gemma":[0.04088959,0.004274487,0.5840943,0.02391034,0.002628426,0.002236234,0.02256771,0.003856347,0.00000326615,0.05255085,0.2590043,0.003984136],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.1241793,0.8711885,0.00007876447,0.0009095713,0.0004393579,0.002214004,0.0006089624,0.00001054339,0.0003710056],"genre_scores_gemma":[0.3616303,0.6363974,0.0005879125,0.0003808343,0.0003208349,0.0004209476,0.0001661078,0.00006386065,0.00003182481],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.2822302,"threshold_uncertainty_score":0.9999905,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.5342640919627406,"score_gpt":0.5376408697069376,"score_spread":0.003376777744196979,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}